解放军医学杂志2017，Vol.42Issue(11)：1020-1024,5.DOI:10.11855/j.issn.0577-7402.2017.11.16
常染色体显性遗传性多囊肾病的诊疗进展
Advances in diagnosis and treatment of autosomal dominant polycystic kidney disease
摘要
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common single-gene inherited kidney disease,and also the fourth leading cause of end-stage renal disease (ESRD).Currently,no effective treatment exists to delay ADPKD progression.In recent years,there has been great progress in gene research,diagnosis and treatment of ADPKD.Moreover,clinical trials were conducted using somatostatin analogs and vasopressin receptor antagonists,and resulted in the approval of tolvaptan in treatment of ADPKD in some countries.The relevant research status and developments of ADPKD will be summarized in the present paper focusing on the diagnosis and treatment of the disease.关键词
常染色体显性遗传性多囊肾病/诊断/药物治疗Key words
autosomal dominant polycystic kidney disease/diagnosis/drug therapy分类
医药卫生引用本文复制引用
吴晓媛,白雪源..常染色体显性遗传性多囊肾病的诊疗进展[J].解放军医学杂志,2017,42(11):1020-1024,5.基金项目
国家自然科学基金(81770663、81570659) （81770663、81570659）
国家重点研发计划(2016YFA0101002)This work was supported by the National Natural Science Foundation of China (81770663,81570659) and the National Basic Research Program of China (2016YFA0101002) （2016YFA0101002）
